Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.
Leung NHL, Cheng SMS, Martín-Sánchez M, Au NYM, Ng YY, Luk LLH, Chan KCK, Li JKC, Leung YWY, Tsang LCH, Chaothai S, Kwan KKH, Ip DKM, Poon LLM, Leung GM, Peiris JSM, Cowling BJ. Leung NHL, et al. Among authors: cheng sms. Clin Infect Dis. 2023 Feb 8;76(3):e299-e307. doi: 10.1093/cid/ciac458. Clin Infect Dis. 2023. PMID: 35675370 Free PMC article. Clinical Trial.
Strength and durability of antibody responses to BNT162b2 and CoronaVac.
Cowling BJ, Wong IOL, Shiu EYC, Lai AYT, Cheng SMS, Chaothai S, Kwan KKH, Martín-Sánchez M, Poon LLM, Ip DKM, Leung GM, Leung NHL, Peiris JSM. Cowling BJ, et al. Among authors: cheng sms. Vaccine. 2022 Jul 30;40(32):4312-4317. doi: 10.1016/j.vaccine.2022.05.033. Epub 2022 Jun 11. Vaccine. 2022. PMID: 35701327 Free article.
Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
Leung NHL, Cheng SMS, Cohen CA, Martín-Sánchez M, Au NYM, Luk LLH, Tsang LCH, Kwan KKH, Chaothai S, Fung LWC, Cheung AWL, Chan KCK, Li JKC, Ng YY, Kaewpreedee P, Jia JZ, Ip DKM, Poon LLM, Leung GM, Peiris JSM, Valkenburg SA, Cowling BJ. Leung NHL, et al. Among authors: cheng sms. Lancet Microbe. 2023 Sep;4(9):e670-e682. doi: 10.1016/S2666-5247(23)00216-1. Epub 2023 Aug 4. Lancet Microbe. 2023. PMID: 37549680 Free PMC article. Clinical Trial.
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.
Cheng SMS, Mok CKP, Li JKC, Chan KKP, Luk KS, Lee BHW, Gu H, Chan KCK, Tsang LCH, Yiu KYS, Ling KKC, Tang YS, Luk LLH, Yu JKM, Pekosz A, Webby RJ, Cowling BJ, Hui DSC, Peiris M. Cheng SMS, et al. Virol J. 2024 Mar 21;21(1):70. doi: 10.1186/s12985-024-02335-9. Virol J. 2024. PMID: 38515117 Free PMC article.
Neutralizing antibody titres in SARS-CoV-2 infections.
Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, Ko RLW, Chan KH, Cheng SMS, Perera RAPM, Cowling BJ, Poon LLM, Peiris M. Lau EHY, et al. Among authors: cheng sms. Nat Commun. 2021 Jan 4;12(1):63. doi: 10.1038/s41467-020-20247-4. Nat Commun. 2021. PMID: 33397909 Free PMC article.
Resurgence of Omicron BA.2 in SARS-CoV-2 infection-naive Hong Kong.
Xie R, Edwards KM, Adam DC, Leung KSM, Tsang TK, Gurung S, Xiong W, Wei X, Ng DYM, Liu GYZ, Krishnan P, Chang LDJ, Cheng SMS, Gu H, Siu GKH, Wu JT, Leung GM, Peiris M, Cowling BJ, Poon LLM, Dhanasekaran V. Xie R, et al. Among authors: cheng sms. Nat Commun. 2023 Apr 27;14(1):2422. doi: 10.1038/s41467-023-38201-5. Nat Commun. 2023. PMID: 37105966 Free PMC article.
41 results